Sugi Predict

Sugi Predict / Compounds / SCHEMBL343208

SCHEMBL343208

SCHEMBL343208

O=C(O)c1cc(C(F)(F)F)ccc1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ HPGD P15428 2/20 0.53
▸ FOLH1 Q04609 1/20 0.53
▸ CYP2C8 P10632 1/20 0.53
▸ PTGDR2 Q9Y5Y4 2/20 0.52
▸ ALOX5AP P20292 1/20 0.52
▸ FEN1 P39748 1/20 0.52
▸ BACE1 P56817 1/20 0.50
▸ TACR1 P25103 2/20 0.49
▸ FABP4 P15090 2/20 0.48
▸ TAS2R14 Q9NYV8 2/20 0.48
▸ RORC P51449 1/20 0.48
▸ RORB Q92753 1/20 0.48
▸ CES2 O00748 1/20 0.47
▸ KIF11 P52732 1/20 0.47
▸ USP2 O75604 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ FABP5 Q01469 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7763180 0.98 HSD17B10 (0.51) HSD17B10ALDH1A1KDM4EHPGDFOLH1
SCHEMBL28662231 0.87 BCAT2 (0.56) HSD17B10ALDH1A1KDM4EHPGDCYP2C8
SCHEMBL6639339 0.87 PTGDR2 (0.50) HSD17B10ALDH1A1KDM4EHPGDCYP2C8
SCHEMBL4860528 0.87 FOLH1 (0.50) HSD17B10ALDH1A1KDM4EHPGDFOLH1
SCHEMBL27620640 0.86 PTGDR2 (0.45) HSD17B10ALDH1A1KDM4EHPGDFOLH1
SCHEMBL421844 0.86 ALDH1A1 (0.57) HSD17B10ALDH1A1KDM4EHPGDCYP2C8
SCHEMBL593792 0.86 ALOX5AP (0.53) HSD17B10ALDH1A1KDM4EHPGDCYP2C8
SCHEMBL593241 0.85 CYP2C8 (0.52) HSD17B10ALDH1A1KDM4EHPGDCYP2C8
SCHEMBL4859217 0.84 FOLH1 (0.51) HSD17B10FOLH1CYP2C8PTGDR2ALOX5AP
SCHEMBL28757559 0.83 PTGDR2 (0.50) ALDH1A1CYP2C8PTGDR2BACE1TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1515541-A Method for detecting ligand pair combination by using non-fluorescent marker and its composite ռ�˹ 2004-07-28 — — CN claimed
EP-0832069-B1 BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION PFIZER (US) 2003-03-05 — — EP claimed
CN-1212019-A Methods and compositions for detecting ligand pair binding using non-fluorescent labels RAPIGENE INC (US) 1999-03-24 — — CN claimed
CN-110128346-A A kind of biaryl amide pyrazole derivatives and its preparation method and application 南开大学 2019-08-16 — — CN disclosed
US-10138206-B2 Amorphous form of lomitapide mesylate GLENMARK PHARMACEUTICALS LIMITED (IN) 2018-11-27 — — US disclosed
US-20170305858-A1 AMORPHOUS FORM OF LOMITAPIDE MESYLATE GLENMARK LIFE SCIENCES LIMITED (IN) 2017-10-26 — — US disclosed
WO-2016055934-A1 AMORPHOUS FORM OF LOMITAPIDE MESYLATE GLENMARK PHARMACEUTICALS LIMITED (IN) 2016-04-14 — — WO disclosed
CN-101678019-B Piperidine/piperazine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2016-03-30 — — CN disclosed
CN-102781942-B Octahydro pyrrolo-[3,4-c] pyrroles is replaced as two of orexin receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2015-09-23 — — CN disclosed
US-20120016152-A1 Process for the preparation of 4`-haloalkylbiphenyl-2-carboxylic acids SALTIGO GMBH (DE) 2012-01-19 — — US disclosed
EP-2366680-A2 Method for manufacturing 4'-halogenalkyl-biphenyl-2-carboxylic acids Saltigo GmbH (DE) 2011-09-21 — — EP disclosed
WO-1997049708-A9 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS — 1998-05-22 — — WO disclosed
WO-1997049708-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS AMERICAN CYANAMID COMPANY (US) 1997-12-31 — — WO disclosed
WO-1997043255-A1 INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 1997-11-20 — — WO disclosed
WO-1997043257-A1 INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 1997-11-20 — — WO disclosed
EP-0804440-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS American Cyanamid Company (US) 1997-11-05 — — EP disclosed
EP-0804438-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS American Cyanamid Company (US) 1997-11-05 — — EP disclosed
WO-1997026240-A1 CONFORMATIONALLY RESTRICTED AROMATIC INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 1997-07-24 — — WO disclosed
US-4578522-A CHEMICAL INTERMEDIATES FOR BLOOD LIPID CONTROLLING COMPOUNDS BURROUGHS WELLCOME CO. 1986-03-25 — — US disclosed
EP-0059983-A1 Substituted biphenyl compounds for use as a medicament THE WELLCOME FOUNDATION LIMITED (GB) 1982-09-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016152-A1 Process for the preparation of 4`-haloalkylbiphenyl-2-carboxylic acids CYP4B1, HACL2, UGT1A4 HSD17B10 125/4885ALDH1A1 110/4885KDM4E 553/4885
US-10138206-B2 Amorphous form of lomitapide mesylate LIPA, AUP1, LPXN HSD17B10 1603/4885ALDH1A1 3292/4885KDM4E 2336/4885
US-20170305858-A1 AMORPHOUS FORM OF LOMITAPIDE MESYLATE LIPA, AUP1, LPXN HSD17B10 1603/4885ALDH1A1 3292/4885KDM4E 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.